Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation - PubMed (original) (raw)

. 2024 Jan-Dec;16(1):2307568.

doi: 10.1080/19490976.2024.2307568. Epub 2024 Feb 1.

Shivani Devi 2, Goo Hyun Kwon 1, Haripriya Gupta 1, Jin-Ju Jeong 1, Satya Priya Sharma 1, Sung-Min Won 1, Ki-Kwang Oh 1, Sang Jun Yoon 1, Hee Jin Park 1, Jung A Eom 1, Min Kyo Jeong 1, Ji Ye Hyun 1, Nattan Stalin 2, Tae-Sik Park 2, Jieun Choi 3, Do Yup Lee 3, Sang Hak Han 4, Dong Joon Kim 1, Ki Tae Suk 1

Affiliations

Gut microbiota-derived indole compounds attenuate metabolic dysfunction-associated steatotic liver disease by improving fat metabolism and inflammation

Byeong Hyun Min et al. Gut Microbes. 2024 Jan-Dec.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease, and its prevalence has increased worldwide in recent years. Additionally, there is a close relationship between MASLD and gut microbiota-derived metabolites. However, the mechanisms of MASLD and its metabolites are still unclear. We demonstrated decreased indole-3-propionic acid (IPA) and indole-3-acetic acid (IAA) in the feces of patients with hepatic steatosis compared to healthy controls. Here, IPA and IAA administration ameliorated hepatic steatosis and inflammation in an animal model of WD-induced MASLD by suppressing the NF-κB signaling pathway through a reduction in endotoxin levels and inactivation of macrophages. Bifidobacterium bifidum metabolizes tryptophan to produce IAA, and B. bifidum effectively prevents hepatic steatosis and inflammation through the production of IAA. Our study demonstrates that IPA and IAA derived from the gut microbiota have novel preventive or therapeutic potential for MASLD treatment.

Keywords: Bifidobacterium; Metabolic dysfunction-associated steatotic liver disease; gut microbiome; indole; metabolite.

PubMed Disclaimer

Conflict of interest statement

No potential conflict of interest was reported by the author(s).

Figures

None

Graphical abstract

Figure 1.

Figure 1.

Human data.

Figure 2.

Figure 2.

IPA and IAA ameliorate WD-induced hepatic steatosis.

Figure 3.

Figure 3.

Administration of IPA and IAA alleviates WD-induced hepatic steatosis and inflammation in mice.

Figure 4.

Figure 4.

Administration of IPA and IAA suppresses the increase in endotoxin and the inflammatory response caused by WD.

Figure 5.

Figure 5.

IPA and IAA treatment altered transcriptomic in the liver.

Figure 6.

Figure 6.

Modulating microbial taxonomic abundance of IPA and IAA on WD-induced changes.

Figure 7.

Figure 7.

B. bifidum ameliorates WD-induced hepatic steatosis.

Figure 8.

Figure 8.

Administration of B. bifidum alleviates WD-induced hepatic steatosis and inflammation in mice.

References

    1. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ.. Mechanisms of NAFLD development and therapeutic strategies. Nat Med. 2018;24(7):908–22. doi: 10.1038/s41591-018-0104-9. - DOI - PMC - PubMed
    1. Kawaguchi T, Tsutsumi T, Nakano D, Eslam M, George J, Torimura T. MAFLD enhances clinical practice for liver disease in the Asia-Pacific region. Clin Mol Hepatol. 2022;28(2):150–163. doi: 10.3350/cmh.2021.0310. - DOI - PMC - PubMed
    1. Fukunaga S, Mukasa M, Nakano D, Tsutsumi T, Kawaguchi T. Changing from NAFLD to MASLD: similar cumulative incidence of reflux esophagitis between NAFLD and MASLD. Clin Mol Hepatol. 2024;30(1):121–123. doi: 10.3350/cmh.2023.0437. - DOI - PMC - PubMed
    1. Parry SA, Hodson L. Influence of dietary macronutrients on liver fat accumulation and metabolism. J Invest Med. 2017;65(8):1102–15. doi: 10.1136/jim-2017-000524. - DOI - PMC - PubMed
    1. Blandino G, Inturri R, Lazzara F, Di Rosa M, Malaguarnera L. Impact of gut microbiota on diabetes mellitus. Diabetes Metab. 2016;42(5):303–15. doi: 10.1016/j.diabet.2016.04.004. - DOI - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources